

AMEDISYS INC
Form 10-Q
August 02, 2011
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 0-24260

AMEDISYS, INC.

(Exact Name of Registrant as Specified in its Charter)

Edgar Filing: AMEDISYS INC - Form 10-Q

Delaware **11-3131700**
(State or other jurisdiction of (I.R.S. Employer

incorporation or organization) Identification No.)
5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date, is as follows: Common stock, \$0.001 par value, 29,259,058 shares outstanding as of July 29, 2011.

Table of Contents

TABLE OF CONTENTS

| | |
|--|----|
| <u>SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION</u> | 1 |
| <u>PART I. FINANCIAL INFORMATION</u> | |
| ITEM 1. FINANCIAL STATEMENTS (UNAUDITED): | |
| <u>CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2011 AND DECEMBER 31, 2010</u> | 2 |
| <u>CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2011 AND 2010</u> | 3 |
| <u>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTH PERIODS ENDED JUNE 30, 2011 AND 2010</u> | 4 |
| <u>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</u> | 5 |
| ITEM 2. <u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u> | 15 |
| ITEM 3. <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u> | 25 |
| ITEM 4. <u>CONTROLS AND PROCEDURES</u> | 25 |
| <u>PART II. OTHER INFORMATION</u> | |
| ITEM 1. <u>LEGAL PROCEEDINGS</u> | 26 |
| ITEM 1A. <u>RISK FACTORS</u> | 26 |
| ITEM 2. <u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u> | 27 |
| ITEM 3. <u>DEFAULTS UPON SENIOR SECURITIES</u> | 27 |
| ITEM 4. <u>RESERVED</u> | 27 |
| ITEM 5. <u>OTHER INFORMATION</u> | 27 |
| ITEM 6. <u>EXHIBITS</u> | 28 |
| <u>SIGNATURES</u> | 30 |
| <u>INDEX TO EXHIBITS</u> | 31 |

Table of Contents

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION

Special Caution Concerning Forward-Looking Statements

When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (SEC), or in statements made by or on behalf of our company, words like believes, belief, expects, plans, anticipates, intends, projects, estimates, may, might, would, should and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, adverse effects of a failure of the Federal government to fund government programs in which we participate, such as Medicare or Medicaid, adverse effects of a possible delay in the Federal budget process or a Federal government shutdown, our ability to open agencies, acquire additional agencies and integrate and operate these agencies effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, changes in or developments with respect to any litigation or investigations relating to the Company, including the United States Senate Committee on Finance inquiry, the SEC investigation and the U.S. Department of Justice Civil Investigative Demand and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2010, filed with the SEC on February 22, 2011, particularly Part I, Item 1A. Risk Factors therein, which are incorporated herein by reference and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.

Available Information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled Investors on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link SEC filings) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link Corporate Governance).

Additionally, our filings can be obtained at the SEC's Public Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. Our electronically filed reports can also be obtained on the SEC's internet site at <http://www.sec.gov>.

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****AMEDISYS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

(Amounts in thousands, except share data)

(Unaudited)

| | June 30, 2011 | December 31, 2010 |
|--|---------------------|----------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 28,132 | \$ 120,295 |
| Patient accounts receivable, net of allowance for doubtful accounts of \$18,162 and \$20,977 | 153,273 | 141,549 |
| Prepaid expenses | 10,976 | 9,947 |
| Other current assets | 12,400 | 22,259 |
| Total current assets | 204,781 | 294,050 |
| Property and equipment, net of accumulated depreciation of \$77,832 and \$78,074 | 144,446 | 138,554 |
| Goodwill | 901,611 | 791,412 |
| Intangible assets, net of accumulated amortization of \$19,130 and \$17,135 | 62,331 | 53,393 |
| Other assets, net | 27,478 | 22,454 |
| Total assets | \$ 1,340,647 | \$ 1,299,863 |
| LIABILITIES AND EQUITY | | |
| Current liabilities: | | |
| Accounts payable | \$ 21,843 | \$ 20,663 |
| Payroll and employee benefits | 78,077 | 82,961 |
| Accrued expenses | 70,014 | 61,254 |
| Current portion of long-term obligations | 35,448 | 37,178 |
| Current portion of deferred income taxes | 10,408 | 14,285 |
| Total current liabilities | 215,790 | 216,341 |
| Long-term obligations, less current portion | 127,901 | 144,688 |
| Deferred income taxes | 61,516 | 52,286 |
| Other long-term obligations | 5,460 | 6,833 |
| Total liabilities | 410,667 | 420,148 |
| Commitments and Contingencies - Note 6 | | |
| Equity: | | |
| Preferred stock, \$0.001 par value, 5,000,000 shares authorized; none issued or outstanding | | |
| Common stock, \$0.001 par value, 60,000,000 shares authorized; 30,575,814 and 29,867,701 shares issued; and 29,890,269 and 29,232,807 shares outstanding | 30 | 29 |
| Additional paid-in capital | 422,273 | 407,156 |
| Treasury stock at cost, 685,545 and 634,894 shares of common stock | (15,702) | (14,022) |
| Accumulated other comprehensive income | 15 | 25 |
| Retained earnings | 521,612 | 484,669 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | |
|---|--------------|--------------|
| Total Amedisys, Inc. stockholders' equity | 928,228 | 877,857 |
| Noncontrolling interests | 1,752 | 1,858 |
| Total equity | 929,980 | 879,715 |
| Total liabilities and equity | \$ 1,340,647 | \$ 1,299,863 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INCOME STATEMENTS

(Amounts in thousands, except per share data)

(Unaudited)

| | For the Three-Month Periods Ended June 30, | | For the Six-Month Periods Ended June 30, | |
|--|---|------------|---|------------|
| | 2011 | 2010 | 2011 | 2010 |
| Net service revenue | \$ 373,722 | \$ 422,349 | \$ 738,024 | \$ 835,316 |
| Cost of service, excluding depreciation and amortization | 193,147 | 209,293 | 384,326 | 413,352 |
| General and administrative expenses: | | | | |
| Salaries and benefits | 80,862 | 88,586 | 166,512 | 175,553 |
| Non-cash compensation | 3,205 | 3,168 | 5,115 | 5,681 |
| Other | 46,644 | 52,431 | 92,209 | 97,446 |
| Provision for doubtful accounts | 2,128 | 4,463 | 5,290 | 8,808 |
| Depreciation and amortization | 9,726 | 8,279 | 19,081 | 16,465 |
| Operating expenses | 335,712 | 366,220 | 672,533 | 717,305 |
| Operating income | 38,010 | 56,129 | 65,491 | 118,011 |
| Other (expense) income: | | | | |
| Interest income | 89 | 92 | 207 | 177 |
| Interest expense | (2,254) | (2,350) | (4,506) | (4,761) |
| Equity in earnings from unconsolidated joint ventures | 466 | 734 | 789 | 1,522 |
| Miscellaneous, net | (425) | (1,576) | (764) | (1,543) |
| Total other expense, net | (2,124) | (3,100) | (4,274) | (4,605) |
| Income before income taxes | 35,886 | 53,029 | 61,217 | 113,406 |
| Income tax expense | (14,175) | (20,663) | (24,182) | (44,210) |
| Net income | 21,711 | 32,366 | 37,035 | 69,196 |
| Net income attributable to noncontrolling interests | (55) | (164) | (91) | (348) |
| Net income attributable to Amedisys, Inc. | \$ 21,656 | \$ 32,202 | \$ 36,944 | \$ 68,848 |
| Net income per share attributable to Amedisys, Inc. common stockholders: | | | | |
| Basic | \$ 0.76 | \$ 1.15 | \$ 1.30 | \$ 2.46 |
| Diluted | \$ 0.75 | \$ 1.13 | \$ 1.28 | \$ 2.42 |
| Weighted average shares outstanding: | | | | |
| Basic | 28,625 | 28,106 | 28,495 | 27,963 |
| Diluted | 29,010 | 28,597 | 28,938 | 28,478 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents**AMEDISYS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(Amounts in thousands)

(Unaudited)

| | For the Six-Month Periods Ended June 30, | |
|---|---|-----------|
| | 2011 | 2010 |
| Cash Flows from Operating Activities: | | |
| Net income | \$ 37,035 | \$ 69,196 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 19,081 | 16,465 |
| Provision for doubtful accounts | 5,290 | 8,808 |
| Non-cash compensation | 5,115 | 5,681 |
| 401(k) employer match | 3,332 | 11,467 |
| Loss on disposal of property and equipment | 1,313 | 2,019 |
| Deferred income taxes | 3,708 | 6,074 |
| Equity in earnings of unconsolidated joint ventures | (789) | (1,522) |
| Amortization of deferred debt issuance costs | 788 | 788 |
| Return on equity investment | 540 | 840 |
| Changes in operating assets and liabilities, net of impact of acquisitions: | | |
| Patient accounts receivable | (3,320) | (10,395) |
| Other current assets | 10,117 | 11,256 |
| Other assets | (6,364) | (2,915) |
| Accounts payable | (357) | 5,368 |
| Accrued expenses | 2,398 | 1,641 |
| Other long-term obligations | (1,374) | 663 |
| Net cash provided by operating activities | 76,513 | 125,434 |
| Cash Flows from Investing Activities: | | |
| Proceeds from sale of deferred compensation plan assets | 853 | 2,340 |
| Purchases of deferred compensation plan assets | (379) | (1,018) |
| Purchases of property and equipment | (26,032) | (23,910) |
| Acquisitions of businesses, net of cash acquired | (125,977) | (2,721) |
| Acquisitions of reacquired franchise rights | | (2,377) |
| Net cash used in investing activities | (151,535) | (27,686) |
| Cash Flows from Financing Activities: | | |
| Proceeds from issuance of stock upon exercise of stock options and warrants | 236 | 1,358 |
| Proceeds from issuance of stock to employee stock purchase plan | 2,731 | 3,012 |
| Tax benefit from stock option exercises | (334) | 2,192 |
| Non-controlling interest distribution | (198) | (185) |
| Principal payments of long-term obligations | (19,576) | (22,583) |
| Net cash used in financing activities | (17,141) | (16,206) |
| Net (decrease) increase in cash and cash equivalents | (92,163) | 81,542 |
| Cash and cash equivalents at beginning of period | 120,295 | 34,485 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | |
|---|-----------|------------|
| Cash and cash equivalents at end of period | \$ 28,132 | \$ 116,027 |
| Supplemental Disclosures of Cash Flow Information: | | |
| Cash paid for interest | \$ 3,656 | \$ 4,266 |
| Cash paid for income taxes, net of refunds received | \$ 6,273 | \$ 31,870 |
| Supplemental Disclosures of Non-Cash Financing and Investing Activities: | | |
| Notes payable issued for acquisitions | \$ | \$ 750 |
| Notes payable issued for software licenses | \$ | \$ 10,801 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS

Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (Amedisys, we, us, or our) are a multi-state provider of home health and hospice services with approximately 84% and 86% of our revenue derived from Medicare for the three-month periods ended June 30, 2011 and 2010, respectively and approximately 85% and 87% of our revenue derived from Medicare for the six-month periods ended June 30, 2011 and 2010, respectively. As of June 30, 2011, we had 485 Medicare-certified home health and 90 Medicare-certified hospice agencies in 45 states within the United States, the District of Columbia and Puerto Rico.

Basis of Presentation

In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission (SEC) on February 22, 2011 (the Form 10-K), which includes information and disclosures not included herein.

Use of Estimates

Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications and Comparability

Certain reclassifications have been made to prior periods' financial statements in order to conform them to the current period's presentation.

Principles of Consolidation

These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.

Equity Investments

We consolidate subsidiaries and/or joint ventures when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.

For subsidiaries or joint ventures in which we do not have a controlling interest or for which we are not the primary beneficiary, we record such investments under the equity method of accounting.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

We earn net service revenue through our home health and hospice agencies by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day episode of care as episodic-based revenue.

Table of Contents

When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results.

Home Health Revenue Recognition

Medicare Revenue

Net service revenue is recorded under the Medicare prospective payment system (PPS) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (LUPA) if the number of visits was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (thresholds set at 6, 14 and 20 visits); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare Program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

In addition to the items noted above, the Centers for Medicare and Medicaid Services (CMS) recently added two new provisions to PPS which was implemented April 1, 2011: (1) a face-to-face encounter requirement and (2) changes to the therapy assessment schedule which require additional patient evaluations and certifications. As a condition for Medicare payment, the first new provision mandates that prior to certifying a patient's eligibility for the home health benefit, the certifying physician must document that he or she, or an allowed non-physician practitioner, has had a face-to-face encounter with the patient. The encounter must occur in the timeframe of 90 days prior to the start of care or 30 days after the start of care. Documentation regarding these encounters must be present on certifications. Under the second new provision, CMS imposed therapy assessment requirements. An assessment by a professional qualified therapist must take place at least once every 30 days during a therapy patient's course of treatment. For those qualified patients expecting to require 13 or 19 therapy visits, a qualified therapist must perform the therapy service required, assess the patient, and measure and document effectiveness on the 13th visit and the 19th visit. This requirement applies to each therapy discipline caring for the patient, but the assessment may be performed close to, but no later than, the 13th and 19th visits. Management evaluates the potential for revenue adjustments as a result of these regulations, and when appropriate, provides allowances for losses based upon the best available information.

We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. In addition, management evaluates the potential for revenue adjustments and, when appropriate, provides allowances for losses based upon the best available information. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of June 30, 2011 and 2010, the difference between the cash received from Medicare for a request for anticipated payment (RAP) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods.

Non-Medicare Revenue

Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service

Edgar Filing: AMEDISYS INC - Form 10-Q

revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.

Table of Contents

Hospice Revenue Recognition

Hospice Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four main levels of care we provide are routine care, general inpatient care, continuous home care and respite care. Routine care accounts for 97% of our total net Medicare hospice service revenue for the three and six-month periods ended June 30, 2011, respectively, as compared to 98% and 97% for the three and six-month periods ended June 30, 2010, respectively. We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable.

Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. We have settled our Medicare hospice reimbursements for all fiscal years through October 31, 2009. For the cap years ended October 31, 2010 and October 31, 2011, we have \$3.2 million recorded for estimated amounts due back to Medicare in other accrued liabilities as of June 30, 2011 and \$1.9 million recorded as of December 31, 2010. As a result of our adjustments, we believe our revenue and patients accounts receivable are recorded at amounts that will be ultimately realized.

Effective April 1, 2011, CMS implemented its hospice regulation requiring that a hospice physician or nurse practitioner have a face-to-face encounter with hospice patients during the 30 day period prior to the 180th-day recertification (third benefit period) and each subsequent recertification, to gather clinical findings to determine continued eligibility for hospice care, and that the certifying hospice physician attest that such a visit took place. Management evaluates the potential for revenue adjustments due to these regulations and when appropriate provides allowances for losses based upon the best available information.

Hospice Non-Medicare Revenue

We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable.

Patient Accounts Receivable

Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. There is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables, and thus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 360 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible.

We believe the credit risk associated with our Medicare accounts, which represent 71% and 76% of our net patient accounts receivable at June 30, 2011 and December 31, 2010, respectively, is limited due to (i) our historical collection rate of over 99% from Medicare and (ii) the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. During the three and six-month periods ended June 30, 2011, we recorded \$2.5 million and \$4.9 million, respectively, in estimated revenue adjustments to Medicare revenue as compared to \$1.5 million and \$1.7 million during the three and six-month periods ended June 30, 2010, respectively.

We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.

Table of Contents*Medicare Home Health*

For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (final billed). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted.

Medicare Hospice

For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient.

Non-Medicare Home Health and Hospice

For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. We estimate an allowance for doubtful accounts to reduce the carrying amount of the receivables to the amounts we estimate will be ultimately collected. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. In addition, the amount of the allowance for doubtful accounts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectibility based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and fair value differ (amounts in millions):

| Financial Instrument | Fair Value at Reporting Date Using | | |
|-----------------------|---|-----------------------------|---|
| | Quoted Prices in Active Markets for Identical Items Significant Other Significant | | |
| | As of June 30, 2011 | (Level 1) Observable Inputs | (Level 2) Other Significant (Level 3) Unobservable Inputs |
| Long-term obligations | \$ 163.3 | \$ | \$ 171.3 |

The estimates of the fair value of our long-term obligations are based upon a discounted present value analysis of future cash flows. Due to the existing uncertainty in the capital and credit markets, the actual rates that would be obtained to borrow under similar conditions could materially differ from the estimates we have used.

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:

Level 1 Quoted prices in active markets for identical assets and liabilities.

Edgar Filing: AMEDISYS INC - Form 10-Q

Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable and accrued expenses, we estimate the carrying amounts approximate fair value due to their short term maturity. Our deferred compensation plan assets are recorded at fair value.

Weighted-Average Shares Outstanding

Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income per share

Table of Contents

attributable to Amedisys, Inc. common stockholders and the shares which were anti-dilutive to the computation (amounts in thousands):

| | For the Three-Month Periods Ended June 30, | | For the Six-Month Periods Ended June 30, | |
|--|---|---------------|---|---------------|
| | 2011 | 2010 | 2011 | 2010 |
| Weighted average number of shares outstanding - basic | 28,625 | 28,106 | 28,495 | 27,963 |
| Effect of dilutive securities: | | | | |
| Stock options | 80 | 151 | 86 | 163 |
| Non-vested stock and stock units | 305 | 340 | 357 | 352 |
| Weighted average number of shares outstanding - diluted | 29,010 | 28,597 | 28,938 | 28,478 |
| Anti-dilutive securities | 2 | 53 | | |

Recently Issued Accounting Pronouncements

In June 2011, the FASB issued Accounting Standards Update (ASU) 2011-05, *Comprehensive Income (Topic 220): Presentation of Comprehensive Income* requiring entities to present net income and other comprehensive income in either a single continuous statement or in two separate, but consecutive, statements of net income and other comprehensive income. The option to present items of other comprehensive income in the statement of changes in equity is eliminated. The ASU is effective for fiscal years and interim periods within those years, beginning after December 15, 2011, with early adoption permitted. We do not expect the adoption of this ASU to have a material impact on our consolidated financial statements.

In July 2011, the FASB ratified the final Emerging Issues Task Force Consensus on Issue No. 09-H, *Health Care Entities: Presentation and Disclosure of Net Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts*. The Consensus will require health care entities to separately present bad debt expense related to patient service revenue as a reduction to patient service revenue (net of contractual allowances and discounts). Health care entities will be required to disclose qualitative and quantitative information about the activity in the allowance for doubtful accounts, and their policies for assessing collectability in determining the timing and amount of revenue and bad debt expense. The Consensus will be effective for fiscal years and interim periods within those years beginning after December 15, 2011, with early application permitted. Retrospective application will be required for presenting bad debt expense related to patient service revenue as a reduction of revenue. The expanded disclosures are required to be applied prospectively. We expect the adoption of this final Consensus to decrease our net service revenue by the amount of the provision for doubtful accounts recorded, which will decrease gross margin; however, it will have no effect on net income.

3. ACQUISITIONS

We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy.

2011 Acquisitions

On June 7, 2011, we acquired Beacon Hospice, Inc. (Beacon) for a total purchase price of \$126.0 million, net of cash acquired (subject to certain adjustments), of which \$8.2 million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Beacon owns and operates 22 hospice agencies and one inpatient unit servicing the states of Massachusetts, Maine, New Hampshire, Rhode Island and Connecticut. In connection with the acquisition, we recorded substantially the entire purchase price as goodwill (\$110.2 million), other intangibles (\$10.9 million) and other assets and liabilities, net (\$4.9 million).

Edgar Filing: AMEDISYS INC - Form 10-Q

The following table contains pro forma condensed consolidated income statement information assuming that the Beacon transaction closed on January 1, 2010, for the six-month periods ended June 30, 2011 and 2010 (amounts in thousands, except per share data):

| | 2011 | 2010 |
|----------------------------|----------|----------|
| Net service revenue | \$ 771.7 | \$ 865.3 |
| Operating income | 68.1 | 120.5 |
| Net income | 37.6 | 69.6 |
| Basic earnings per share | \$ 1.32 | \$ 2.49 |
| Diluted earnings per share | \$ 1.30 | \$ 2.44 |

Table of Contents**4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET**

The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of and for the six-month period ended June 30, 2011 (amounts in millions):

| | Home Health | Goodwill Hospice | Total |
|-------------------------------|-------------|---------------------|----------|
| Balances at December 31, 2010 | \$ 723.3 | \$ 68.1 | \$ 791.4 |
| Additions | | 110.2 | 110.2 |
| Balances at June 30, 2011 | \$ 723.3 | \$ 178.3 | \$ 901.6 |

| | Certificates of Need and Licenses | Other Intangible Assets, Net Acquired Names of Business (1) | Non-Compete Agreements & Reacquired Franchise Rights (2) | Total |
|-------------------------------|---|--|--|---------|
| Balances at December 31, 2010 | \$ 41.7 | \$ 4.7 | \$ 7.0 | \$ 53.4 |
| Additions | 2.5 | 8.1 | 0.3 | 10.9 |
| Amortization | | (0.1) | (1.9) | (2.0) |
| Balances at June 30, 2011 | \$ 44.2 | \$ 12.7 | \$ 5.4 | \$ 62.3 |

- (1) Acquired Names of Business includes \$12.5 million of unamortized acquired names and \$0.2 million of amortized acquired names which have a weighted-average amortization period of 2.3 years.
- (2) The weighted-average amortization period of our non-compete agreements and reacquired franchise rights is 2.3 and 2.0 years, respectively.

5. LONG-TERM OBLIGATIONS

Long-term obligations, including capital lease obligations, consisted of the following for the periods indicated (amounts in millions):

| | June 30, 2011 | December 31, 2010 |
|--|---------------|-------------------|
| Senior Notes: | | |
| \$35.0 million Series A Notes; semi-annual interest only payments; interest rate at 6.07% per annum; due March 25, 2013 | \$ 35.0 | \$ 35.0 |
| \$30.0 million Series B Notes; semi-annual interest only payments; interest rate at 6.28% per annum; due March 25, 2014 | 30.0 | 30.0 |
| \$35.0 million Series C Notes; semi-annual interest only payments; interest rate at 6.49% per annum; due March 25, 2015 | 35.0 | 35.0 |
| \$150.0 million Term Loan; \$7.5 million principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (0.94% at June 30, 2011); due March 26, 2013 | 52.5 | 67.5 |
| Promissory notes | 10.8 | 14.4 |
| | 163.3 | 181.9 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | |
|--|-----------------|-----------------|
| Current portion of long-term obligations | (35.4) | (37.2) |
| Total | \$ 127.9 | \$ 144.7 |

Revolving Credit Facility

On May 26, 2011, we entered into a First Amendment to our \$250.0 Million Revolving Credit Facility (the *First Amendment*). Under the terms of the First Amendment, (i) the financial covenant baskets relating to permitted *Investments in Joint Ventures* and *other Investments* were increased to give the Company greater flexibility, (ii) there was a non-substantive, clarifying amendment to the definition of *Permitted Acquisition* and (iii) certain other agreements, obligations and representations and warranties of the parties thereto were amended, modified and/or supplemented. In connection with the execution of the First Amendment, each existing guarantor under the Credit Agreement consented to the terms of the First Amendment.

Our weighted-average interest rate for our five year Term Loan for the three and six-month periods ended June 30, 2011 was 1.0% as compared to 1.1% for the three and six-month periods ended June 30, 2010.

As of June 30, 2011, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.9 and our fixed charge coverage ratio was 1.5.

Table of Contents

As of June 30, 2011, our availability under our \$250.0 million Revolving Credit Facility was \$231.3 million as we had \$18.7 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

6. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows. We are also involved in the legal actions set forth below.

United States Senate Committee on Finance Inquiry

On May 12, 2010, we received a letter of inquiry from the United States Senate Committee on Finance requesting documents and information relating to our policies and practices regarding home therapy visits and therapy utilization trends. A similar letter was sent to the other major publicly traded home health care companies. We are cooperating with the Committee with respect to this inquiry.

Securities Class Action Lawsuits

On June 7, 2010, a putative securities class action complaint was filed in the United States District Court for the Middle District of Louisiana against the Company and certain of our current and former senior executives. Additional putative securities class actions were filed in the United States District Court for the Middle District of Louisiana on July 14, July 16, and July 28, 2010.

On October 22, 2010, the Court issued an order consolidating the putative securities class action lawsuits and the derivative actions (described immediately below) for pre-trial purposes. In the same order, the Court appointed the Public Employees Retirement System of Mississippi and the Puerto Rico Teachers Retirement System as co-lead plaintiffs (together, the Co-Lead Plaintiffs) for the putative class. On December 10, 2010, the Court also consolidated the ERISA class action lawsuit (described below) with the putative securities class actions and derivative actions for pre-trial purposes.

On January 18, 2011, the Co-Lead Plaintiffs filed an amended, consolidated class action complaint (the Securities Complaint) which supersedes the earlier-filed securities class action complaints. The Securities Complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The Securities Complaint seeks a determination that the action may be maintained as a class action on behalf of all persons who purchased the Company's securities between August 2, 2005 and September 28, 2010. All defendants have moved to dismiss the Securities Complaint.

Derivative Actions

On July 2, 2010, an alleged shareholder of the Company filed a derivative lawsuit in the United States District Court for the Middle District of Louisiana, purporting to assert claims on behalf of the Company against certain of our current and former officers and directors. Three similar derivative suits were filed in the United States District Court for the Middle District of Louisiana on July 15, July 21, and August 2, 2010. We are named as a nominal defendant in all of those actions. As noted above, on October 22, 2010, the United States District Court for the Middle District of Louisiana issued an order consolidating the derivative actions with the putative securities class action lawsuits and for pre-trial purposes.

On January 18, 2011, the plaintiffs in the consolidated federal derivative actions filed a consolidated, amended complaint (the Derivative Complaint) which supersedes the earlier-filed derivative complaints. The Derivative Complaint alleges that certain of our current and former officers and directors breached their fiduciary duties to the Company by making allegedly false statements, by allegedly failing to establish sufficient internal controls over certain of our home health and Medicare billing practices, by engaging in alleged insider trading, and by committing unspecified acts of waste of corporate assets and unjust enrichment. All defendants in the derivative action, including the Company as a nominal defendant, have moved to dismiss the Derivative Complaint.

Edgar Filing: AMEDISYS INC - Form 10-Q

On July 23, 2010, a derivative suit was filed in the Nineteenth Judicial District Court, Parish of East Baton Rouge, State of Louisiana. That action also purports to assert claims on behalf of the Company against certain of our current and former officers and directors. On December 8, 2010, the Court entered an order staying the action in deference to the earlier-filed derivative actions pending in federal court.

Table of Contents

ERISA Class Action Lawsuit

On September 27, 2010 and October 22, 2010, separate putative class action complaints were filed in the United States District Court for the Middle District of Louisiana against us, certain of our current and former senior executives and members of our 401(k) Plan Administrative Committee. The suits allege violations of the Employee Retirement Income Security Act (ERISA) since January 1, 2006 and July 1, 2007, respectively. The plaintiffs brought the complaints on behalf of themselves and a class of similarly situated participants in our 401(k) plan. The plaintiffs assert that the defendants breached their fiduciary duties to the 401(k) Plan's participants by causing the 401(k) plan to offer and hold Amedisys common stock during the respective class periods when it was an allegedly unduly risky and imprudent retirement investment because of our alleged improper business practices. The complaints seek a determination that the actions may be maintained as a class action, an award of unspecified monetary damages and other unspecified relief. As noted above, on December 10, 2010, the Court consolidated the putative ERISA class actions with the putative securities class actions and derivative actions for pre-trial purposes. In addition, on December 10, 2010, the Court appointed interim lead counsel and interim liaison counsel in the ERISA class action.

On March 10, 2011, Wanda Corbin, Pia Galimba and Linda Trammell (the Co-ERISA Plaintiffs), filed an amended, consolidated class action complaint (the ERISA Complaint), which supersedes the earlier-filed ERISA class action complaints. The ERISA Complaint seeks a determination that the action may be maintained as a class action on behalf of themselves and a class of similarly situated participants in our 401(k) plan from January 1, 2008 through present. All of the defendants have moved to dismiss the ERISA Complaint.

SEC Investigation

On June 30, 2010, we received notice of a formal investigation from the SEC and received a subpoena for documents relating to the matters under review by the United States Senate Committee on Finance and other matters involving our operations. We are cooperating with the SEC with respect to this investigation.

U.S. Department of Justice Civil Investigative Demand (CID)

On September 27, 2010, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act. The CID requires the delivery of a wide range of documents and information to the United States Attorney's Office for the Northern District of Alabama, relating to the Company's clinical and business operations, including reimbursement and billing claims submitted to Medicare for home health services, and related compliance activities. The CID generally covers the period from January 1, 2003. On April 26, 2011, we received a second CID related to the CID issued in September 2010, which generally covers the same time period as the previous CID and requires the production of additional documents. We are cooperating with the Department of Justice with respect to this investigation.

We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the United States Senate Committee on Finance inquiry, the SEC investigation, the U.S. Department of Justice CIDs and the securities, shareholder derivative and ERISA litigation described above given the preliminary stage of these matters. The Company intends to continue to vigorously defend itself in the securities, shareholder derivative and ERISA litigation matters. No assurances can be given as to the timing or outcome of the United States Senate Committee on Finance inquiry, the SEC investigation, the U.S. Department of Justice CIDs or the securities, shareholder derivative and ERISA litigation matters described above or the impact of any of the inquiry, investigation or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows.

We recognize that additional putative securities class action complaints and other litigation could be filed, and that other investigations and actions could be commenced, relating to matters involving our home therapy visits and therapy utilization trends or other matters.

Third Party Audits

We are subject in the ordinary course of our business from time to time to audits under various governmental programs in which third party firms engaged by CMS conduct extensive review of claims data to identify potential improper payments under the Medicare program.

In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare Program Safeguard Contractor (PSC) a request for records regarding 137 claims submitted by the subsidiary paid from January 2, 2008 through November 10, 2009 (the Claim Period) to determine whether the underlying services met pertinent Medicare payment requirements. Based on the PSC's findings, which were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim Period, on March 9, 2011, the Medicare Administrative Contractor for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately \$5.6 million. We dispute these findings and intend to vigorously seek to have these findings overturned, but no assurances can be given as to the timing or outcome of any appeal. As of June 30, 2011, we have no liability recorded for this claim.

Edgar Filing: AMEDISYS INC - Form 10-Q

In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor (ZPIC) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the

Table of Contents

period of January 1, 2008 through March 31, 2010 (the Review Period) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations. Based on the ZPIC 's findings, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the Medicare Administrative Contractor for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately \$5.5 million. We dispute these findings and intend to vigorously seek to have these findings overturned, but no assurances can be given as to the timing or outcome of any appeal. In the event we pay any amount of this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. As of June 30, 2011, we have no liability recorded for this claim.

Insurance

We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.

Our health insurance has a retention limit of \$750.0 thousand, our workers' compensation insurance has a retention limit of \$350.0 thousand and our professional liability insurance has a retention limit of \$250.0 thousand.

Investments

In June 2011, we purchased a limited partnership interest for \$2.0 million in a private investment fund. The purpose of the fund is to identify, fund and develop innovative solutions that have the potential to improve quality, reduce cost, and increase efficiency across a continuum of care for healthcare delivery systems. In addition, we have committed an additional \$18.0 million capital contribution to the fund on an as needed basis.

7. SEGMENT INFORMATION

Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the home of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. The other column in the following tables consists of costs relating to corporate support functions that are not directly attributable to a specific segment.

Table of Contents

Management evaluates performance and allocates resources based on the operating income of the reportable segments, which exclude corporate expenses, but includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below. The following table summarizes our segment information for the periods indicated (amounts in millions):

| | For the Three-Month Period Ended June 30, 2011 | | | |
|--|---|----------------|--------------|--------------|
| | Home Health | Hospice | Other | Total |
| Net service revenue | \$ 326.4 | \$ 47.3 | \$ | \$ 373.7 |
| Cost of service, excluding depreciation and amortization | 167.6 | 25.5 | | 193.1 |
| General and administrative expenses | 73.5 | 9.7 | 47.6 | 130.8 |
| Provision for doubtful accounts | 2.2 | (0.1) | | 2.1 |
| Depreciation and amortization | 3.8 | 0.2 | 5.7 | 9.7 |
| Operating expenses | 247.1 | 35.3 | 53.3 | 335.7 |
| Operating income | \$ 79.3 | \$ 12.0 | \$ (53.3) | \$ 38.0 |

| | For the Three-Month Period Ended June 30, 2010 | | | |
|--|---|----------------|--------------|--------------|
| | Home Health | Hospice | Other | Total |
| Net service revenue | \$ 388.0 | \$ 34.3 | \$ | \$ 422.3 |
| Cost of service, excluding depreciation and amortization | 190.7 | 18.6 | | 209.3 |
| General and administrative expenses | 91.1 | 7.9 | 45.1 | 144.1 |
| Provision for doubtful accounts | 4.0 | 0.5 | | 4.5 |
| Depreciation and amortization | 3.9 | 0.1 | 4.3 | 8.3 |
| Operating expenses | 289.7 | 27.1 | 49.4 | 366.2 |
| Operating income | \$ 98.3 | \$ 7.2 | \$ (49.4) | \$ 56.1 |

| | For the Six-Month Period Ended June 30, 2011 | | | |
|--|---|----------------|--------------|--------------|
| | Home Health | Hospice | Other | Total |
| Net service revenue | \$ 651.9 | \$ 86.1 | \$ | \$ 738.0 |
| Cost of service, excluding depreciation and amortization | 338.4 | 45.9 | | 384.3 |
| General and administrative expenses | 150.2 | 17.8 | 95.8 | 263.8 |
| Provision for doubtful accounts | 5.4 | (0.1) | | 5.3 |
| Depreciation and amortization | 7.0 | 0.3 | 11.8 | 19.1 |
| Operating expenses | 501.0 | 63.9 | 107.6 | 672.5 |
| Operating income | \$ 150.9 | \$ 22.2 | \$ (107.6) | \$ 65.5 |

| | For the Six-Month Period Ended June 30, 2010 | | | |
|--|---|----------------|--------------|--------------|
| | Home Health | Hospice | Other | Total |
| Net service revenue | \$ 768.5 | \$ 66.8 | \$ | \$ 835.3 |
| Cost of service, excluding depreciation and amortization | 377.7 | 35.7 | | 413.4 |
| General and administrative expenses | 177.4 | 15.7 | 85.5 | 278.6 |
| Provision for doubtful accounts | 7.8 | 1.0 | | 8.8 |
| Depreciation and amortization | 7.5 | 0.2 | 8.8 | 16.5 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | | | |
|--------------------|----------|---------|-----------|----------|
| Operating expenses | 570.4 | 52.6 | 94.3 | 717.3 |
| Operating income | \$ 198.1 | \$ 14.2 | \$ (94.3) | \$ 118.0 |

Table of Contents**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and six-month periods ended June 30, 2011. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission (SEC) on February 22, 2011 (the Form 10-K), which are incorporated herein by this reference.

Unless otherwise provided, Amedisys, we, us, our and the Company refer to Amedisys, Inc. and our consolidated subsidiaries.

Overview

We are a leading provider of high-quality, low-cost home health services to the chronic, co-morbid, aging American population. Our services include home health and hospice services, and approximately 84% and 86% of our revenue was derived from Medicare for the three-month periods ended June 30, 2011 and 2010, respectively and approximately 85% and 87% of our revenue was derived from Medicare for the six-month periods ended June 30, 2011 and 2010, respectively. During the three-month period ended June 30, 2011, we had \$373.7 million in net service revenue, earnings per diluted share of \$0.75 and cash flow from operations of \$24.0 million. For the six-month period ended June 30, 2011, we had \$738.0 million in net service revenue, earnings per diluted share of \$1.28 and cash flow from operations of \$76.5 million.

Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. As of June 30, 2011, we had 485 Medicare-certified home health and 90 Medicare-certified hospice agencies in 45 states within the United States, the District of Columbia and Puerto Rico as detailed below:

| | Owned and Operated Agencies | |
|----------------------|-----------------------------|---------|
| | Home health | Hospice |
| At December 31, 2010 | 486 | 67 |
| Acquisitions | | 22 |
| Start-ups | 6 | 2 |
| Closed/Consolidated | (7) | (1) |
| At June 30, 2011 | 485 | 90 |

When we refer to same store business, we mean home health and hospice agencies that we have operated for at least the last twelve months; when we refer to acquisitions, we mean home health and hospice agencies that we acquired within the last twelve months; and when we refer to start-ups, we mean any home health or hospice agency opened by us in the last twelve months. Once an agency has been in operation for a twelve month period, the results for that particular agency are included as part of our same store business from that date forward. When we refer to episodic-based revenue, admissions, recertifications or completed episodes, we mean home health revenue, admissions, recertifications or completed episodes of care for those payors that pay on an episodic-basis, which includes Medicare and other insurance carriers including Medicare Advantage programs.

Recent Developments*Governmental Inquiries and Investigations and Stockholder Litigation*

See Note 6 to our condensed consolidated financial statements for a discussion of the recent governmental inquiry, investigations and subsequent stockholder litigation we are involved in. No assurances can be given as to the timing or outcome of these items.

Health Care Reform

Edgar Filing: AMEDISYS INC - Form 10-Q

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act of 2010 (HCERA), which amends the PPACA (collectively, the Health Care Reform Bills). The Health Care Reform Bills make a number of changes to Medicare payment rates, including the reinstatement of the 3% home health rural add-on, which began on April 1, 2010 (expiring January 1, 2016). The Health Care Reform Bills also include a systemic rebasing of the amount Centers for Medicare and Medicaid Services (CMS) reimburses for home health services, to be phased in over four years, beginning in 2014. We anticipate that many of the provisions of the Health Care Reform Bills may be subject to further clarification and modification through the rule-making process. It is uncertain at this time the effect the rebasing will have on our future results of operations or cash flows.

Table of Contents

Face-to-Face and Therapy Requirements

In November 2010, CMS issued a rule which finalized two new provisions of the PPACA which ultimately were implemented April 1, 2011: (1) a face-to-face encounter requirement for home health and hospice and (2) changes in the therapy assessment schedule. As a condition for Medicare payment, the PPACA mandates that prior to certifying a patient's eligibility for the home health benefit, the certifying physician must document that he or she, or an allowed non-physician practitioner, has had a face-to-face encounter with the patient. The encounter must occur in the timeframe of 90 days prior to the start of care or 30 days after the start of care. Documentation regarding these encounters must be present on certifications.

A hospice rule for the implementation of a PPACA provision requiring that a hospice physician or nurse practitioner have a face-to-face encounter with hospice patients during the 30 day period prior to the 180th-day recertification (third benefit period) and each subsequent recertification, and that the certifying hospice physician attest that such a visit took place.

The face-to-face encounter requirement for home health and hospice providers was to become effective January 1, 2011. However, due to concerns that some providers may need additional time to establish operational protocols necessary to comply with face-to-face encounter requirements, CMS delayed full enforcement of the requirements until April 1, 2011.

In addition, the November rule imposed important therapy assessment requirements. An assessment by a professional qualified therapist must take place at least once every 30 days during a therapy patient's course of treatment. For those qualified patients expecting to require 13 or 19 therapy visits, a qualified therapist must perform the therapy service required, assess the patient, and measure and document effectiveness on the 13th visit and the 19th visit. This requirement applies to each therapy discipline caring for the patient but for multi-discipline episodes the assessment may be performed close to, but no later than, 13th and 19th visits.

Payment

In July 2011, CMS issued a final rule to update and revise the Medicare hospice wage index for fiscal year 2012. The proposed rule includes a 3.0% market basket update, a 0.1% increase for the updated wage index data and the third year of the 7-year phase out of the budget neutrality adjustment factor of 0.6%. The net effect of the final rule increases the base rate for 2012 by 2.5%. The final rule also includes two options for the hospice cap calculation methodology. We do not expect the changes to have a material impact on our future results of operations or financial condition.

In July 2011, CMS issued a proposed rule to update and revise Medicare home health rates for calendar year 2012. The proposed rule includes a 1.5% market basket increase which includes the 1% reduction mandated by the Health Care Reform Bills and a negative 5.06% nominal change in case-mix adjustment. The net effect of these changes decreases the base rate by 3.6% to \$2,112. The proposed rule also shifts case mix points from high case mix and high therapy episodes to low case mix and non-therapy episodes. CMS has not issued a final rule as of the date of this filing. The final rule is expected to be published in October 2011.

In July 2011, CMS issued a proposed rule that revised the Medicaid home health definition to add a requirement, similar to the finalized Medicare home health requirement, that a physician or non-physician practitioner perform a face-to-face encounter with the Medicaid eligible individual and the physician must document that the face-to-face encounter occurred. Under the proposed rule, the face-to-face encounter must occur no more than 90 days prior to the start of services under the Medicaid home health benefit or, in certain circumstances, within 30 days after the start of home health services. CMS has not issued a final rule as of the date of this filing. The final rule is expected to be published in October 2011.

Results of Operations

Three-Month Period Ended June 30, 2011 Compared to the Three-Month Period Ended June 30, 2010

During the three month period ended June 30, 2011, we incurred certain costs associated with acquisitions and related integration costs and incurred certain costs associated with our realignment of our operations during the three month period ended June 30, 2010. Included in these certain costs are legal expenses related to the United States Senate Committee on Finance inquiry and the SEC and DOJ investigations discussed in Note 6 to the condensed consolidated financial statements. These costs were offset by the reversal of accrued bonuses and CMS bonus payments as the result of the pay for performance demonstration. The following details these items (amounts in millions, except per share data):

Edgar Filing: AMEDISYS INC - Form 10-Q

| | For the Three-Months Ended June 30, 2011 | | | | For the Three-Months Ended June 30, 2010 | | | |
|-----------------|--|--------------------------|---------------|----------------|--|--------------------------|-----------------|------------------|
| | Financial | | | | Financial | | | |
| | Statement Line Item Impacted | | | | Statement Line Item Impacted | | | |
| | Net Service Revenue | Other Operating Expenses | Net of Tax | Diluted EPS | Net Service Revenue | Other Operating Expenses | Net of Tax | Diluted EPS |
| Bonus reversal | \$ | \$ 1.5 | \$ 0.9 | \$ 0.03 | \$ | \$ 3.1 | \$ 1.9 | \$ 0.07 |
| CMS Bonus | 4.7 | | 2.9 | 0.10 | 3.6 | | 2.2 | 0.08 |
| Exit activities | | | | | | (1.5) | (0.9) | (0.03) |
| Certain costs | | (2.6) | (1.6) | (0.05) | | (6.4) | (3.9) | (0.14) |
| Total | \$ 4.7 | \$ (1.1) | \$ 2.2 | \$ 0.08 | \$ 3.6 | \$ (4.8) | \$ (0.7) | \$ (0.02) |

Consolidated

The following table summarizes our consolidated results of operations (amounts in millions):

| | For the Three-Month Periods Ended June 30, | |
|---|--|----------|
| | 2011 | 2010 |
| Net service revenue | \$ 373.7 | \$ 422.3 |
| Gross margin | 180.6 | 213.0 |
| <i>% of revenue</i> | 48.3% | 50.4% |
| Other operating expenses | 142.6 | 156.9 |
| <i>% of revenue</i> | 38.2% | 37.2% |
| Operating income | 38.0 | 56.1 |
| Income tax expense | 14.2 | 20.7 |
| <i>Effective income tax rate</i> | 39.5% | 39.0% |
| Net income attributable to Amedisys, Inc. | \$ 21.7 | \$ 32.2 |

Table of Contents

Our net service revenue declined \$48.6 million from prior year primarily due to significant decrease in our home health division. Our operating income decreased \$18.1 million over prior year with approximately \$18.0 million resulting from the 2011 CMS rate cut impacting the home health division. In our efforts to mitigate the impact of the rate cut, we have reduced our other operating expenses by \$14.3 million and lowered our cost per visit. However, our admissions, recertifications and revenue per episode were below prior year performance on a total and same store basis which significantly impacted our operating performance. Our hospice division continued its growth in volumes and contribution and added a significant acquisition (Beacon Hospice, Inc., Beacon) to the divisional portfolio.

Home Health Division

The following table summarizes our home health segment results of operations:

| | For the Three-Month Periods Ended June 30, | | | | | |
|---|--|----------------------------|----------------|----------------|--------------|----------------|
| | 2011 | | | 2010 | | |
| | Same Store | Start-ups/ Acquisitions | Total | Same Store | Other (1) | Total |
| Financial Information (in millions): | | | | | | |
| Episodic-based revenue | \$ 302.7 | \$ 5.0 | \$ 307.7 | \$ 356.1 | \$ 13.2 | \$ 369.3 |
| Nonepisodic-based revenue | 18.4 | 0.3 | 18.7 | 17.9 | 0.8 | 18.7 |
| Net service revenue | 321.1 | 5.3 | 326.4 | 374.0 | 14.0 | 388.0 |
| Same store episodic-based revenue growth (2) | (15)% | | | 6% | | |
| Cost of service | 164.2 | 3.4 | 167.6 | 179.9 | 10.8 | 190.7 |
| Gross margin | 156.9 | 1.9 | 158.8 | 194.1 | 3.2 | 197.3 |
| Other operating expenses | 76.5 | 3.0 | 79.5 | 85.7 | 13.3 | 99.0 |
| Operating income | \$ 80.4 | \$ (1.1) | \$ 79.3 | \$ 108.4 | \$ (10.1) | \$ 98.3 |
| Key Statistical Data: | | | | | | |
| Admissions: | | | | | | |
| Episodic-based | 57,799 | 1,181 | 58,980 | 60,426 | 2,650 | 63,076 |
| Nonepisodic-based | 10,400 | 204 | 10,604 | 9,577 | 511 | 10,088 |
| Total admissions | 68,199 | 1,385 | 69,584 | 70,003 | 3,161 | 73,164 |
| Same store episodic-based admission growth (2) | (4)% | | | 4% | | |
| Recertifications: | | | | | | |
| Episodic-based | 43,751 | 464 | 44,215 | 46,025 | 1,545 | 47,570 |
| Nonepisodic-based | 4,374 | 39 | 4,413 | 4,623 | 113 | 4,736 |
| Total recertifications | 48,125 | 503 | 48,628 | 50,648 | 1,658 | 52,306 |
| Same store episodic-based recertification growth (2) | (5)% | | | (9)% | | |
| Completed episodes | 99,593 | 1,553 | 101,146 | 104,951 | 4,469 | 109,420 |
| Visits: | | | | | | |
| Episodic-based | 1,904,019 | 29,063 | 1,933,082 | 2,034,885 | 72,568 | 2,107,453 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | | | | | |
|---|------------------|---------------|------------------|------------------|---------------|------------------|
| Nonepisodic-based | 200,058 | 3,666 | 203,724 | 202,300 | 10,983 | 213,283 |
| Total visits | 2,104,077 | 32,729 | 2,136,806 | 2,237,185 | 83,551 | 2,320,736 |
| Cost per visit | \$ 78.04 | \$ 106.34 | \$ 78.47 | \$ 80.44 | \$ 128.66 | \$ 82.18 |
| Average episodic-based revenue per completed episode (3) | \$ 3,032 | \$ 3,189 | \$ 3,034 | \$ 3,378 | \$ 3,243 | \$ 3,372 |
| Episodic-based visits per completed episode (4) | 18.9 | 18.3 | 18.9 | 19.4 | 17.7 | 19.4 |

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same store episodic-based revenue, admissions or recertifications growth is the percent increase (decrease) in our same store episodic-based revenue, admissions or recertifications for the period as a percent of the same store episodic-based revenue, admissions or recertifications of the prior period.
- (3) Average episodic-based revenue per completed episode is the average episodic-based revenue earned for each episodic-based completed episode of care.
- (4) Episodic-based visits per completed episode is the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.

Table of Contents

Net Service Revenue

Our home health revenue is driven by the volume of admissions and recertifications and the revenue per episode realized on episodes completed and in progress during the quarter. We experienced significant declines in all of these metrics which contributed to a \$61.6 million decline in our home health net service revenue.

Admissions and recertifications accounted for approximately \$26.0 million of the decline as we experienced negative same store episodic-based admissions and recertification growth during the quarter. These declines include the impact of agencies we closed or merged in 2010. We believe our admission volumes were negatively impacted by the CMS face-to-face requirements, which became effective April 1, 2011. However, we believe that we have successfully implemented this regulation and have recorded a reserve of approximately \$0.6 million as an estimate of our failure to receive certifications from the physicians for admissions currently in our patient census. While we cannot fully measure the impact of lower admissions due to the unwillingness of physicians to refer to home health as a result of this regulation, we do believe that it has impacted current admissions and it could impact future admissions. The decline in recertifications is due to a lower patient census as our rate of recertifications has remained stable on a sequential basis and over prior year.

Our revenue per episode decline of 10% has resulted in approximately a \$36.0 million decline in revenue with approximately \$18.0 million as a result of the 5.2% CMS rate cut for 2011 with the remainder due to a reduction in the therapy needs of our patients and the impact of the new CMS therapy assessment regulations effective April 1, 2011. We had approximately 30,000 non-billable therapy visits due to our failure to meet the requirements of the regulation. While this is only 1.5% of our total visits performed, it resulted in an estimated \$4.0 million reduction in revenue. We will continue to have non-billable therapy visits in the third quarter, but expect to see a gradual improvement in the number of non-billable therapy visits.

In addition to changes in volume and revenue per episode, 2011 benefited from the accrual of a \$4.7 million CMS bonus payment compared to a \$3.6 million CMS bonus payment we received in 2010.

Cost of Service, excluding Depreciation and Amortization

The decline in cost per visit is due primarily to our conversion of therapists to our pay per visit models, our focus on productivity, our portfolio realignment and a decline in therapy visits. We anticipate our same store cost per visit to remain stable, absent the impact of holidays, however, any material change in the level of service needed by our patients could impact this metric.

Other Operating Expenses

Our other operating expenses decreased \$19.5 million in total and \$9.2 million on a same store basis with the primary drivers being a decline in salary and benefits and additional cost reductions in our remaining portfolio. Additionally, the second quarter of 2010 included approximately \$2.0 million in certain costs related to agencies we closed or merged in 2010.

Table of Contents**Hospice Division**

The following table summarizes our hospice segment results of operations:

| | For the Three-Month Periods Ended June 30, | | | | | |
|---|--|----------------------------|---------|------------|-----------|---------|
| | 2011 | | | 2010 | | |
| | Same Store | Start-ups/ Acquisitions | Total | Same Store | Other (1) | Total |
| Financial Information (in millions): | | | | | | |
| Medicare revenue | \$ 37.5 | \$ 6.6 | \$ 44.1 | \$ 30.8 | \$ 1.5 | \$ 32.3 |
| Non-Medicare revenue | 2.7 | 0.5 | 3.2 | 1.9 | 0.1 | 2.0 |
| Net service revenue | 40.2 | 7.1 | 47.3 | 32.7 | 1.6 | 34.3 |
| Same store Medicare revenue growth (2) | 22% | | | 22% | | |
| Cost of service | 21.0 | 4.5 | 25.5 | 17.2 | 1.4 | 18.6 |
| Gross margin | 19.2 | 2.6 | 21.8 | 15.5 | 0.2 | 15.7 |
| Other operating expenses | 7.7 | 2.1 | 9.8 | 7.3 | 1.2 | 8.5 |
| Operating income | \$ 11.5 | \$ 0.5 | \$ 12.0 | \$ 8.2 | \$ (1.0) | \$ 7.2 |

Key Statistical Data:

| | | | | | | |
|-------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Hospice admits | 3,140 | 600 | 3,740 | 2,676 | 198 | 2,874 |
| Hospice days | 301,724 | 42,629 | 344,353 | 246,575 | 11,597 | 258,172 |
| Average daily census | 3,316 | 468 | 3,784 | 2,710 | 127 | 2,837 |
| Revenue per day | \$ 133.04 | \$ 166.52 | \$ 137.18 | \$ 132.61 | \$ 139.11 | \$ 132.90 |
| Cost of service per day | \$ 69.37 | \$ 106.43 | \$ 73.96 | \$ 69.45 | \$ 126.69 | \$ 72.02 |
| Average length of stay | 88 | 73 | 86 | 88 | 63 | 87 |

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same Store Medicare revenue growth is the percent increase in our same store Medicare revenue for the period as a percent of the same store Medicare revenue of the prior period

Net Service Revenue

Our hospice revenue increased \$13.0 million with \$7.5 million from our same store agencies, \$0.8 million from our start-up agencies and \$6.3 million from our acquisitions offset by \$1.6 million from agencies we closed or merged in 2010. Our acquisition of Beacon contributed \$5.6 million in revenue. Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Our 2011 revenue includes an increase related to an annual hospice rate increase effective October 1, 2010, which was approximately 1.8%. Additionally, our 2011 hospice revenue is net of a \$0.9 million hospice cap adjustment, an increase of \$0.5 million from 2010. Our same store average daily census is up 22% over prior year as we have exceeded same store average daily census in excess of 15% for the past two quarters.

Cost of Service excluding Depreciation and Amortization

Our hospice cost of service increased \$6.9 million (37%) due to the 33% increase in our average daily census over 2010. Our hospice clinicians are generally paid on a salaried basis, and our agencies are staffed based on the average census of the agency.

Other Operating Expenses

Edgar Filing: AMEDISYS INC - Form 10-Q

Our other operating expenses were relatively flat despite our significant increase in revenue. The hospice division benefitted from a \$0.5 million reduction in bad debt expense due to significant improvement in cash collections.

Table of Contents**Six-Month Period Ended June 30, 2011 Compared to the Six-Month Period Ended June 30, 2010**

During the six-month period ended June 30, 2011, we incurred certain costs associated with acquisitions and related integration costs as well as costs associated with agency closings/consolidations we announced in 2010 and incurred certain costs associated with our realignment of our operations during the three-month period ended June 30, 2010. Included in these certain costs are legal expenses related to the United States Senate Committee on Finance inquiry and the SEC and DOJ investigations discussed in Note 6 to the condensed consolidated financial statements. These costs were offset by the reversal of accrued bonuses and CMS bonus payments as the result of the pay for performance demonstration. The following details these items (amounts in millions, except per share data):

| | For the Six-Months Ended June 30, 2011 | | | | For the Six-Months Ended June 30, 2010 | | | |
|-----------------|--|--------------------|--------------------|------------------|--|--------------------|-----------------|------------------|
| | Financial Statement Line Item Impacted | | | | Financial Statement Line Item Impacted | | | |
| | Net Services Revenue | | Operating Expenses | | Net of Tax | | Diluted EPS | |
| | Net Services Revenue | Operating Expenses | Net of Tax | Diluted EPS | Net Services Revenue | Operating Expenses | Net of Tax | Diluted EPS |
| Bonus reversal | \$ 4.7 | \$ 1.5 | \$ 0.9 | \$ 0.03 | \$ 3.6 | \$ 3.1 | \$ 1.9 | \$ 0.07 |
| CMS Bonus | | | 2.9 | 0.10 | | | 2.2 | 0.08 |
| Exit activities | | (1.1) | (0.7) | (0.02) | | (1.5) | (0.9) | (0.03) |
| Certain costs | | (5.9) | (3.6) | (0.12) | | (6.4) | (3.9) | (0.14) |
| Total | \$ 4.7 | \$ (5.5) | \$ (0.5) | \$ (0.01) | \$ 3.6 | \$ (4.8) | \$ (0.7) | \$ (0.02) |

Consolidated

The following table summarizes our consolidated results of operations (amounts in millions):

| | For the Six-Month Periods Ended June 30, | |
|---|--|--------------|
| | 2011 | 2010 |
| Net service revenue | \$ 738.0 | \$ 835.3 |
| Gross margin | 353.7 | 421.9 |
| <i>% of revenue</i> | <i>47.9%</i> | <i>50.5%</i> |
| Other operating expenses | 288.2 | 303.9 |
| <i>% of revenue</i> | <i>39.1%</i> | <i>36.4%</i> |
| Operating income | 65.5 | 118.0 |
| Income tax expense | 24.2 | 44.2 |
| <i>Effective income tax rate</i> | <i>39.5%</i> | <i>39.0%</i> |
| Net income attributable to Amedisys, Inc. | \$ 36.9 | \$ 68.8 |

Net Service Revenue

Our operating income declined \$52.5 million with approximately \$36.0 million of the decline resulting from the 2011 CMS rate cut impacting the home health division. We were able to partially mitigate this impact by an \$8.0 million increase in operating income from our hospice division and a \$30.1 million reduction in operating expenses from our home health division. However, our home health division experienced a decline in episodic volumes and declines in revenue per episode in excess of the rate cut which further impacted our performance. Additionally, we had an increase of \$13.3 million in our corporate support functions primarily related to additional salary costs, depreciation and amortization and legal fees.

Table of Contents**Home Health Division**

The following table summarizes our home health segment results of operations:

| | For the Six-Month Periods Ended June 30, | | | | | |
|---|--|----------------------------|----------------|----------------|--------------|----------------|
| | 2011 | | | 2010 | | |
| | Same Store | Start-ups/ Acquisitions | Total | Same Store | Other (1) | Total |
| Financial Information (in millions): | | | | | | |
| Episodic-based revenue | \$ 603.0 | \$ 11.9 | \$ 614.9 | \$ 703.9 | \$ 27.1 | \$ 731.0 |
| Nonepisodic-based revenue | 36.4 | 0.6 | 37.0 | 35.8 | 1.7 | 37.5 |
| Net service revenue | 639.4 | 12.5 | 651.9 | 739.7 | 28.8 | 768.5 |
| Same store episodic-based revenue growth (2) | (14)% | | | 10% | | |
| Cost of service | 331.1 | 7.3 | 338.4 | 356.2 | 21.5 | 377.7 |
| Gross margin | 308.3 | 5.2 | 313.5 | 383.5 | 7.3 | 390.8 |
| Other operating expenses | 156.1 | 6.5 | 162.6 | 168.5 | 24.2 | 192.7 |
| Operating income | \$ 152.2 | \$ (1.3) | \$ 150.9 | \$ 215.0 | \$ (16.9) | \$ 198.1 |
| Key Statistical Data: | | | | | | |
| Admissions: | | | | | | |
| Episodic-based | 118,957 | 2,503 | 121,460 | 122,871 | 5,483 | 128,354 |
| Nonepisodic-based | 20,904 | 393 | 21,297 | 19,057 | 1,023 | 20,080 |
| Total admissions | 139,861 | 2,896 | 142,757 | 141,928 | 6,506 | 148,434 |
| Same store episodic-based admission growth (2) | (3)% | | | 7% | | |
| Recertifications: | | | | | | |
| Episodic-based | 87,035 | 911 | 87,946 | 94,083 | 3,202 | 97,285 |
| Nonepisodic-based | 8,610 | 80 | 8,690 | 9,408 | 224 | 9,632 |
| Total recertifications | 95,645 | 991 | 96,636 | 103,491 | 3,426 | 106,917 |
| Same store episodic-based recertification growth (2) | (7)% | | | (5)% | | |
| Completed episodes | 197,534 | 3,129 | 200,663 | 205,864 | 8,652 | 214,516 |
| Visits: | | | | | | |
| Episodic-based | 3,809,117 | 60,651 | 3,869,768 | 4,049,413 | 149,293 | 4,198,706 |
| Nonepisodic-based | 397,367 | 6,941 | 404,308 | 399,726 | 21,629 | 421,355 |
| Total visits | 4,206,484 | 67,592 | 4,274,076 | 4,449,139 | 170,922 | 4,620,061 |
| Cost per visit | \$ 78.71 | \$ 108.92 | \$ 79.19 | \$ 80.07 | \$ 125.44 | \$ 81.75 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | | | | | |
|---|----------|----------|-----------------|----------|----------|-----------------|
| Average episodic-based revenue per completed episode (3) | \$ 3,030 | \$ 3,098 | \$ 3,032 | \$ 3,332 | \$ 3,230 | \$ 3,328 |
| Episodic-based visits per completed episode (4) | 18.7 | 17.7 | 18.7 | 19.1 | 17.5 | 19.0 |

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same store episodic-based revenue, admissions or recertifications growth is the percent increase (decrease) in our same store episodic-based revenue, admissions or recertifications for the period as a percent of the same store episodic-based revenue, admissions or recertifications of the prior period.
- (3) Average episodic-based revenue per completed episode is the average episodic-based revenue earned for each episodic-based completed episode of care.
- (4) Episodic-based visits per completed episode is the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.

Table of Contents*Net Service Revenue*

We experienced a decline in all three revenue performance metrics, as our admissions, recertifications and revenue per episode declined over prior year. As mentioned, approximately \$36.0 million of the \$116.6 million decline in revenue is due to the 5.2% CMS rate cut for 2011.

Lower admissions and recertifications accounted for approximately \$55.0 million of the decline. While the recertification rate has stabilized in the current quarter, our rate during the first quarter of 2011 was lower. Same store admission volumes were low for both quarters with the quarter ended June 30, 2011 subject to the face to face requirements.

Overall, revenue per episode decreased by 9% as a result of the 5.2% CMS rate cut for 2011 with the additional reduction primarily due to a reduction in the therapy needs of our patients and the impact of the therapy functional assessment regulation which resulted in approximately 30,000 non-billable visits and a reduction in net service revenue of approximately \$4.0 million.

Cost of Service, excluding Depreciation and Amortization

Our home health cost of service decreased \$39.3 million as we performed 345,985 fewer visits which accounted for \$28.3 million of the decrease with the remainder from the \$2.56 decrease in cost per visit. The cost per visit improvement is due to our portfolio realignment as well as a focus on productivity and conversion of salaried clinicians to our pay per visit model. Except for the impact of additional holidays in the second half of the year, we expect our cost per visit to remain stable.

Other Operating Expenses

Our other operating expenses decreased \$30.1 million in total and \$12.4 million on a same store basis with the primary drivers being a decline in salary and benefits and additional cost reductions in our remaining portfolio.

Hospice Division

The following table summarizes our hospice segment results of operations:

| | For the Six-Month Periods Ended June 30, | | | | | |
|---|--|---------------------------------|---------|------------|-------------------|---------|
| | Same Store | 2011 Start-ups/ Acquisitions | Total | Same Store | 2010 Other (1) | Total |
| Financial Information (in millions): | | | | | | |
| Medicare revenue | \$ 73.2 | \$ 7.4 | \$ 80.6 | \$ 60.3 | \$ 2.8 | \$ 63.1 |
| Non-Medicare revenue | 5.0 | 0.5 | 5.5 | 3.5 | 0.2 | 3.7 |
| Net service revenue | 78.2 | 7.9 | 86.1 | 63.8 | 3.0 | 66.8 |
| Same store Medicare revenue growth (2) | 21% | | | 27% | | |
| Cost of service | 40.6 | 5.3 | 45.9 | 33.0 | 2.7 | 35.7 |
| Gross margin | 37.6 | 2.6 | 40.2 | 30.8 | 0.3 | 31.1 |
| Other operating expenses | 15.1 | 2.9 | 18.0 | 14.6 | 2.3 | 16.9 |
| Operating income | \$ 22.5 | \$ (0.3) | \$ 22.2 | \$ 16.2 | \$ (2.0) | \$ 14.2 |

Key Statistical Data:

| | | | | | | |
|----------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Hospice admits | 6,228 | 709 | 6,937 | 5,305 | 362 | 5,667 |
| Hospice days | 579,224 | 48,874 | 628,098 | 473,056 | 21,635 | 494,691 |
| Average daily census | 3,200 | 270 | 3,470 | 2,614 | 120 | 2,733 |
| Revenue per day | \$ 134.86 | \$ 162.41 | \$ 137.00 | \$ 134.81 | \$ 139.32 | \$ 135.01 |

Edgar Filing: AMEDISYS INC - Form 10-Q

| | | | | | | |
|-------------------------|----------|-----------|----------|----------|-----------|----------|
| Cost of service per day | \$ 69.91 | \$ 109.88 | \$ 73.02 | \$ 69.66 | \$ 126.23 | \$ 72.13 |
| Average length of stay | 89 | 70 | 87 | 89 | 62 | 87 |

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same Store Medicare revenue growth is the percent increase in our same store Medicare revenue for the period as a percent of the same store Medicare revenue of the prior period

Net Service Revenue

Our hospice revenue increased \$19.3 million with \$14.4 million from our same store agencies, \$1.4 million from our start-up agencies and \$6.5 million from our acquisitions offset by \$3.0 million from agencies we closed or merged in 2010. Our Beacon acquisition added \$5.6 million. Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Our 2011 revenue includes an increase related to annual hospice rate increase effective October 1, 2010, which was approximately 1.8%. The growth in our same store revenue is driven by a 22% increase in average daily census. Additionally, our 2011 hospice revenue is net of a \$1.3 million hospice cap adjustment, an increase of \$0.8 million from 2010.

Table of Contents*Cost of Service excluding Depreciation and Amortization*

Our hospice cost of service increased \$10.2 million (29%) due to the 27% increase in our average daily census over 2010. Our hospice clinicians are generally paid on a salaried basis, and our agencies are staffed based on the average census of the agency.

Other Operating Expenses

Our other operating expenses were relatively unchanged despite our significant increase in revenue. The hospice division did benefit from a \$1.0 million reduction in bad debt expense due to significant improvement in cash collections. As our hospice division continues to grow, we do expect to add additional resources in order to meet the needs of our patients and support the growth in the division.

LIQUIDITY AND CAPITAL RESOURCES*Cash Flows for the Six-Month Period Ended June 30, 2011 Compared to the Six-Month Period Ended June 30, 2010*

The following table summarizes our cash flows for the periods indicated (amounts in millions):

| | For the Six-Month Periods Ended June 30, | |
|--|---|-------------|
| | 2011 | 2010 |
| Cash provided by operating activities | \$ 76.5 | \$ 125.4 |
| Cash used in investing activities | (151.5) | (27.7) |
| Cash used in financing activities | (17.2) | (16.2) |
| Net increase in cash and cash equivalents | (92.2) | 81.5 |
| Cash and cash equivalents at beginning of period | 120.3 | 34.5 |
| Cash and cash equivalents at end of period | \$ 28.1 | \$ 116.0 |

Cash provided by operating activities decreased \$48.9 million during 2011 compared to 2010, primarily as a result of changes in net income, accounts payable and other assets.

Cash used in investing activities increased \$123.8 million during 2011 compared to 2010 primarily due to our acquisition of Beacon (\$126.0 million).

Cash used in financing activities increased \$1.0 million during 2011 compared to 2010, primarily due to a decrease in the exercise of stock options, which was offset by a decrease in repayments on our long-term obligations. We decreased our outstanding long-term obligations net of borrowings by \$18.6 million from December 31, 2010.

Liquidity

Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program; however, from time to time, we can and do obtain additional sources of liquidity through sales of our equity or by incurrence of additional indebtedness. As of June 30, 2011, we had \$28.1 million in cash and cash equivalents and \$231.3 million in availability under our \$250.0 million Revolving Credit Facility.

During the six-month period ended June 30, 2011, we spent \$14.9 million in routine capital expenditures, which primarily included equipment, furniture and computer software and \$11.1 million in capital expenditures related to the implementation of our enterprise resource planning system and a company-wide refresh of computer hardware. Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements over the next twelve months and into the foreseeable future.

Outstanding Patient Accounts Receivable

Edgar Filing: AMEDISYS INC - Form 10-Q

Our patient accounts receivable, net increased \$11.8 million from December 31, 2010 to June 30, 2011 primarily due to the acquisition of Beacon which resulted in an increase of \$12.9 million. Our cash collection as a percentage of revenue was 101.6% for the three-month periods ended June 30, 2011 and 99.3% for the three-month periods ended December 31, 2010.

Our patient accounts receivable includes unbilled receivables, which are aged based upon our initial service date. At June 30, 2011, the unbilled patient accounts receivable, as a percentage of gross patient accounts receivable, was 27.4%, or \$48.9 million compared to 28.3% or \$47.9 million at December 31, 2010. We monitor unbilled receivables on an agency by agency basis to ensure that all efforts are made to bill claims within timely filing deadlines. The timely filing deadlines vary by state for Medicaid-reimbursable services and among insurance companies.

Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net service revenue) and provision for doubtful accounts were as follows for the periods indicated (in millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 360 days.

Table of Contents

| | For the Three-Month Periods Ended June 30, | | For the Six-Month Periods Ended June 30, | |
|---|---|---------------|---|----------------|
| | 2011 | 2010 | 2011 | 2010 |
| Provision for estimated revenue adjustments | \$ 2.5 | \$ 1.5 | \$ 4.9 | \$ 1.7 |
| Provision for doubtful accounts | 2.2 | 4.5 | 5.3 | 8.8 |
| Total | \$ 4.7 | \$ 6.0 | \$ 10.2 | \$ 10.5 |
| As a percent of revenue | 1.3% | 1.4% | 1.4% | 1.3% |

The following schedule details our patient accounts receivable, net of estimated revenue adjustments, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding, net):

| | 0-90 | 91-180 | 181-365 | Over 365 | Total |
|---|---------|---------|---------|----------|----------|
| At June 30, 2011: | | | | | |
| Medicare patient accounts receivable, net (1) | \$ 89.4 | \$ 16.6 | \$ 3.0 | \$ | \$ 109.0 |
| Other patient accounts receivable: | | | | | |
| Medicaid | 10.6 | 1.5 | 0.8 | 0.3 | 13.2 |
| Private | 29.3 | 11.6 | 6.0 | 2.4 | 49.3 |
| Total | \$ 39.9 | \$ 13.1 | \$ 6.8 | \$ 2.7 | \$ 62.5 |
| Allowance for doubtful accounts (2) | | | | | (18.2) |
| Non-Medicare patient accounts receivable, net | | | | | \$ 44.3 |
| Total patient accounts receivable, net | | | | | \$ 153.3 |
| Days revenue outstanding, net (3) | | | | | 36.0 |
| | 0-90 | 91-180 | 181-365 | Over 365 | Total |
| At December 31, 2010: | | | | | |
| Medicare patient accounts receivable, net (1) | \$ 89.4 | \$ 16.4 | \$ 1.3 | \$ | \$ 107.1 |
| Other patient accounts receivable: | | | | | |
| Medicaid | 6.0 | 2.2 | 2.0 | 0.1 | 10.3 |
| Private | 27.2 | 9.9 | 7.0 | 1.0 | 45.1 |
| Total | \$ 33.2 | \$ 12.1 | \$ 9.0 | \$ 1.1 | \$ 55.4 |
| Allowance for doubtful accounts (2) | | | | | (21.0) |
| Non-Medicare patient accounts receivable, net | | | | | \$ 34.4 |
| Total patient accounts receivable, net | | | | | \$ 141.5 |
| Days revenue outstanding, net (3) | | | | | 32.8 |

- (1) The following table summarizes the activity and ending balances in our estimated revenue adjustments (amounts in millions), which is recorded to reduce our Medicare outstanding patient accounts receivable to their estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our Medicare claims.

| | For the Three-Month Period | | For the Six-Month Period | |
|---|--|-------------------------|--|--|
| | For the Three-Month Period Ended June 30, 2011 | Ended December 31, 2010 | For the Six-Month Period Ended June 30, 2011 | For the Six-Month Period Ended December 31, 2010 |
| Balance at beginning of period | \$ 6.4 | \$ 6.3 | \$ 6.5 | \$ 6.4 |
| Provision for estimated revenue adjustments | 2.5 | 2.6 | 4.9 | 5.3 |
| Write offs | (2.8) | (2.4) | (5.3) | (5.2) |
| Acquired through acquisitions | 1.1 | | 1.1 | |
| Balance at end of period | \$ 7.2 | \$ 6.5 | \$ 7.2 | \$ 6.5 |

Our estimated revenue adjustments were 6.2% and 5.7% of our outstanding Medicare patient accounts receivable at June 30, 2011 and December 31, 2010, respectively.

- (2) The following table summarizes the activity and ending balances in our allowance for doubtful accounts (amounts in millions), which is recorded to reduce only our Medicaid and private outstanding patient accounts receivable to their estimated net realizable value.

Table of Contents

| | For the Three-Month Period | | For the Six-Month Period | |
|---------------------------------|----------------------------------|-------------------|--------------------------------|-------------------|
| | For the Three-Month Period Ended | Ended | For the Six-Month Period Ended | Ended |
| | Ended June 30, 2011 | December 31, 2010 | Ended June 30, 2011 | December 31, 2010 |
| Balance at beginning of period | \$ 19.1 | \$ 23.0 | \$ 21.0 | \$ 24.5 |
| Provision for doubtful accounts | 2.2 | 5.1 | 5.3 | 10.4 |
| Write offs | (4.4) | (7.1) | (9.4) | (13.9) |
| Acquired through acquisitions | 1.3 | | 1.3 | |
| Balance at end of period | \$ 18.2 | \$ 21.0 | \$ 18.2 | \$ 21.0 |

Our allowance for doubtful accounts was 29.1% and 37.8% of our outstanding Medicaid and private patient accounts receivable at June 30, 2011 and December 31, 2010, respectively.

- (3) Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable (i.e. net of estimated revenue adjustments and allowance for doubtful accounts) at June 30, 2011 and December 31, 2010 by our average daily net patient revenue for the three-month periods ended June 30, 2011 and December 31, 2010, respectively.

Indebtedness*Revolving Credit Facility*

On May 26, 2011, we entered into a First Amendment to our \$250.0 Million Revolving Credit Facility (the *First Amendment*). Under the terms of the First Amendment, (i) the financial covenant baskets relating to permitted Investments in Joint Ventures and other Investments were increased to give the Company greater flexibility, (ii) there was a non-substantive, clarifying amendment to the definition of Permitted Acquisition and (iii) certain other agreements, obligations and representations and warranties of the parties thereto were amended, modified and/or supplemented. In connection with the execution of the First Amendment, each existing guarantor under the Credit Agreement consented to the terms of the First Amendment.

Our weighted-average interest rate for our five year Term Loan for the three and six-month periods ended June 30, 2011 was 1.0% as compared to 1.1% for the three and six-month periods ended June 30, 2010.

As of June 30, 2011, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.9 and our fixed charge coverage ratio was 1.5.

As of June 30, 2011, our availability under our \$250.0 million Revolving Credit Facility was \$231.3 million as we had \$18.7 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

Inflation

We do not believe that inflation has significantly impacted our results of operations.

Critical Accounting Policies

See Part II, Item 7 Critical Accounting Policies and our consolidated financial statements and related notes in Part IV, Item 15 of our 2010 Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting policies include revenue recognition; patient accounts receivable; insurance; goodwill and intangible assets; and income taxes. There have not been any changes to our significant accounting policies or their application, since we filed our 2010 Annual Report on Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Edgar Filing: AMEDISYS INC - Form 10-Q

Our Revolving Credit Facility and Term Loan carry a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate and, therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows will be exposed to changes in interest rates. As of June 30, 2011, the total amount of outstanding debt subject to interest rate fluctuations was \$52.5 million. A 1.0% interest rate increase would increase interest expense by approximately \$0.5 million annually.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures which are designed provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, as of June 30, 2011, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.

Table of Contents

Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2011, the end of the period covered by this Quarterly Report.

Changes in Internal Controls

On January 1, 2011, the Company implemented two modules of a new enterprise resource planning system, PeopleSoft Financials and PeopleSoft Human Capital Management. This implementation was part of our focus on upgrading and enhancing our financial systems and was not in response to any internal control deficiencies. In connection with this system implementation, we are in the process of updating our internal controls over financial reporting, as necessary, to accommodate modifications to our business and accounting processes. We do not believe this implementation will have an adverse affect on our internal controls over financial reporting.

There were no other changes in internal control over financial reporting during the quarter ended June 30, 2011, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls' effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2011, the end of the period covered by this Quarterly Report.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 6 to the condensed consolidated financial statements for information concerning our legal proceedings.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors of our 2010 Annual Report on Form 10-K. The risks described in our 2010 Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes in our risk factors from those disclosed in our 2010 Annual Report on Form 10-K, except for the following:

The economic downturn, any deepening of the economic downturn, continued deficit spending by the Federal government, any failure by the Federal government to raise the debt ceiling, causing the U.S. Treasury to cease making payments under government programs in which we participate, any failure to complete the Federal budget process and fund Federal government operations, resulting in a Federal government shutdown, as well as state budget pressures may result in a reduction in payments and covered services.

Adverse developments in the United States and global economies, continued deficit spending due to economic conditions, bailout programs directed at specific industries or other governmental measures could lead to a reduction in Federal government expenditures, including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition, if at any time the Federal government is not able to meet its debt payments unless the Federal debt ceiling is raised, and legislation increasing the debt ceiling is not enacted, the Federal government may stop or delay making payments on its obligations, including funding for government programs in which we participate, such as

Edgar Filing: AMEDISYS INC - Form 10-Q

Medicare and Medicaid. Failure of the government to make payments under these programs could have a material adverse effect on our business and our consolidated financial condition, results of operations and cash flows. Further, any failure by the United States Congress to complete the Federal budget process and fund government operations may result in a Federal government shutdown, potentially causing us to incur substantial costs without reimbursement under the Medicare program, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Historically, state budget pressures have resulted in reductions in state spending. Given that Medicaid outlays are a significant component of state budgets, we can expect continuing cost containment pressures on Medicaid outlays for our services. In addition, continued unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Table of Contents**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended June 30, 2011:

| Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Share (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
|---------------------------------|--|---|---|--|
| April 1, 2011 to April 30, 2011 | 38,765 | \$ 32.80 | | |
| May 1, 2011 to May 31, 2011 | 6,029 | \$ 33.59 | | |
| June 1, 2011 to June 30, 2011 | 1,212 | \$ 28.42 | | |
| Total | 46,006 (1) | \$ 32.79 | | \$ |

- (1) Includes shares of common stock surrendered to us by certain employees/directors to:
- i. satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees/directors under our 2008 Omnibus Incentive Compensation Plan.
 - ii. satisfy tax withholding obligations in connection with the exercise of stock options previously awarded to such employees/directors under our 1998 Stock Option Plan.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. RESERVED**ITEM 5. OTHER INFORMATION**

None.

Table of Contents**ITEM 6. EXHIBITS**

The exhibits marked with the cross symbol () are filed and the exhibits marked with the double cross symbol () are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

| Exhibit Number | Document Description | Report or Registration Statement | SEC File or Registration Number | Exhibit or Other Reference |
|-----------------------|---|--|--|-----------------------------------|
| 3.1 | Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007 | The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 | 0-24260 | 3.1 |
| 3.2 | Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009 | The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 | 0-24260 | 3.2 |
| 4.1 | Common Stock Specimen | The Company's Registration Statement on Form S-3 filed August 20, 2007 | 333-145582 | 4.8 |
| 4.2 | Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) \$35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) \$30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) \$35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015 | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.1 |
| 4.3 | Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto) | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.2 |
| 4.4 | Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto) | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.3 |
| 4.5 | Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto) | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.4 |
| 10.1 | First Amendment to Credit Agreement dated May 26, 2011 | The Company's Current Report on Form 8-K filed on June 1, 2011 | 0-24260 | 10.1 |
| 10.2* | Retention Bonus Agreement dated April 1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and Michael D. Snow | The Company's Current Report on Form 8-K filed on April 4, 2011 | 0-24260 | 10.1 |
| 10.3* | Retention Bonus Agreement dated April 1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and T.A. Barfield, Jr. | The Company's Current Report on Form 8-K filed on April 4, 2011. | 0-24260 | 10.2 |
| 10.4* | Amended and Restated Amedisys, Inc. employee Stock Purchase Plan effective as of April 1, 2011 | The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 | 0-24260 | 10.1 |
| 31.1 | Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | |

Edgar Filing: AMEDISYS INC - Form 10-Q

- 31.2 Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

| Exhibit | | | SEC File or | Exhibit |
|----------------|--|---|---------------------|------------------|
| Number | Document Description | Report or Registration Statement | Registration | or Other |
| | | | Number | Reference |
| 101.INS | XBRL Instance | | | |
| 101.SCH | XBRL Taxonomy Extension Schema Document | | | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | | | |
| 101.DEF | XBRL Taxonomy Definition Linkbase Document | | | |
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase Document | | | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | | | |

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMEDISYS, INC.
(Registrant)

By: /s/ Dale E. Redman

Dale E. Redman
Chief Financial Officer and

Duly Authorized Officer

DATE: August 2, 2011

Table of Contents**EXHIBIT INDEX**

The exhibits marked with the cross symbol () are filed and the exhibits marked with the double cross symbol () are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

| Exhibit Number | Document Description | Report or Registration Statement | SEC File or Registration Number | Exhibit or Other Reference |
|-----------------------|---|--|--|-----------------------------------|
| 3.1 | Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007 | The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 | 0-24260 | 3.1 |
| 3.2 | Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009 | The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 | 0-24260 | 3.2 |
| 4.1 | Common Stock Specimen | The Company's Registration Statement on Form S-3 filed August 20, 2007 | 333-145582 | 4.8 |
| 4.2 | Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) \$35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) \$30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) \$35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015 | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.1 |
| 4.3 | Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto) | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.2 |
| 4.4 | Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto) | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.3 |
| 4.5 | Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto) | The Company's Current Report on Form 8-K filed on April 1, 2008 | 0-24260 | 4.4 |
| 10.1 | First Amendment to Credit Agreement dated May 26, 2011 | The Company's Current Report on Form 8-K filed on June 1, 2011 | 0-24260 | 10.1 |
| 10.2* | Retention Bonus Agreement dated April 1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and Michael D. Snow | The Company's Current Report on Form 8-K filed on April 4, 2011 | 0-24260 | 10.1 |
| 10.3* | Retention Bonus Agreement dated April 1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and T.A. Barfield, Jr. | The Company's Current Report on Form 8-K filed on April 4, 2011 | 0-24260 | 10.2 |
| 10.4* | Amended and Restated Amedisys, Inc. Employee Stock Purchase Plan effective as of April 1, 2011 | The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 | 0-24260 | 10.1 |
| 31.1 | Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | |

Edgar Filing: AMEDISYS INC - Form 10-Q

- 31.2 Certification of Dale E. Redman, Chief Financial Officer,
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of William F. Borne, Chief Executive Officer,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

| Exhibit Number | Document Description | Report or Registration Statement | SEC File or Registration Number | Exhibit or Other Reference |
|---------------------------|--|---|--|---|
| 32.2 | Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | | |
| 101.INS | XBRL Instance | | | |
| 101.SCH | XBRL Taxonomy Extension Schema Document | | | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | | | |
| 101.DEF | XBRL Taxonomy Definition Linkbase Document | | | |
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase Document | | | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | | | |